Currently, there are 385.00M common shares owned by the public and among those 343.19M shares have been available to trade.
The company’s stock has a 5-day price change of 22.66% and -22.45% over the past three months. MRNA shares are trading -0.41% year to date (YTD), with the 12-month market performance down to -59.37% lower. It has a 12-month low price of $31.94 and touched a high of $170.47 over the same period. MRNA has an average intraday trading volume of 9.52 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.59%, 1.89%, and -50.93% respectively.
Institutional ownership of Moderna Inc (NASDAQ: MRNA) shares accounts for 67.52% of the company’s 385.00M shares outstanding.
It has a market capitalization of $15.94B and a beta (3y monthly) value of 1.58. The earnings-per-share (ttm) stands at -$5.82. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.27% over the week and 7.11% over the month.
Earnings per share for the fiscal year are expected to increase by 25.25%, and 2.46% over the next financial year. EPS should grow at an annualized rate of 17.43% over the next five years, compared to -20.02% over the past 5-year period.
BofA Securities coverage for the Moderna Inc (MRNA) stock in a research note released on December 10, 2024 offered a Underperform rating with a price target of $41. Berenberg was of a view on November 19, 2024 that the stock is Hold, while HSBC Securities gave the stock Buy rating on November 18, 2024, issuing a price target of $58. Wolfe Research on their part issued Underperform rating on November 15, 2024.
